Content :
Who are we?
Impact Malaria
For several decades, sanofi-aventis has operated in Africa and in malaria endemic countries through its subsidiaries and production units.
Our portfolio includes several antimalarial drugs, ranging from quinine to the fixed-dose combination of artesunate and amodiaquine launched in 2007.
Access to medicines
“80% of the world’s population has little or no access to medicines. This is a challenge to be met by the pharmaceutical industry. At sanofi-pasteur, we are committed to developing concrete plans for action…”
Sanofi-aventis Group
Sanofi-aventis is one of the pharmaceutical industry world leaders.
